Pancreatic Cancer Research

ResearcherUniversity of CincinnatiActive in the last 2 years

Gregory C. Wilson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6237-0136; OpenAlex author ID A5035045562. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
84
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 5 papers · 2023: 5 papers · 2024: 1 paper · 2025: none · 2026: 4 papers

Papers 17

  1. Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.hoc.2025.07.010↗
  2. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  3. Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19990-7↗
  4. ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20039-y↗
  5. Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi-institutional ana… Co-author DOI 10.1002/jso.27798↗
  6. Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ductal adenocarcinoma cells in vitro and in v… Co-author DOI 10.1007/s00109-023-02290-y↗
  7. Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00109-023-02331-6↗
  8. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. Co-author DOI 10.1200/po.23.00152↗
  9. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancr… Co-author DOI 10.1245/s10434-022-12741-4↗
  10. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  11. Radiation therapy in borderline resectable pancreatic cancer: A review. Co-author DOI 10.1016/j.surg.2021.12.013↗
  12. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough? Co-author DOI 10.1245/s10434-022-11363-0↗
  13. Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.1245/s10434-022-11580-7↗
  14. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-instit… Co-author DOI 10.1245/s10434-022-11804-w↗
  15. Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancreatic Ductal Adenocarcinoma in an Immunoc… First author DOI 10.3390/cancers14112618↗
  16. A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer: Let the Data Speak. First author DOI 10.1097/sla.0000000000004471↗
  17. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-ins… Co-author DOI 10.1007/s11605-014-2567-4↗

Closest collaborators

The 25 strongest of 84 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sameer H. Patel · 11 shared papers, 2022–2026 · strength 2.25
  2. Syed Ameen Ahmad · 10 shared papers, 2014–2023 · strength 1.32
  3. Syed Arif Ahmad · 4 shared papers, 2023–2026 · strength 0.98
  4. Davendra P. S. Sohal · 5 shared papers, 2022–2026 · strength 0.97
  5. Jordan R. Kharofa · 5 shared papers, 2022–2026 · strength 0.97
  6. Olugbenga Olanrele Olowokure · 5 shared papers, 2022–2026 · strength 0.97
  7. Nipun B. Merchant · 6 shared papers, 2014–2024 · strength 0.77
  8. Shishir Kumar Maithel · 6 shared papers, 2014–2024 · strength 0.77
  9. Syed A. Ahmad · 3 shared papers, 2026 · strength 0.71
  10. Kevin M. Turner · 4 shared papers, 2022–2023 · strength 0.62
  11. David A. Kooby · 5 shared papers, 2014–2024 · strength 0.62
  12. Daniel Erik Abbott · 5 shared papers, 2014–2024 · strength 0.62
  13. Jashodeep Datta · 4 shared papers, 2021–2023 · strength 0.57
  14. Ryan P. Johnson · 2 shared papers, 2026 · strength 0.53
  15. Paul H. McClelland · 2 shared papers, 2026 · strength 0.53
  16. Erich Gulbins · 3 shared papers, 2022–2023 · strength 0.48
  17. Ildikò Szabó · 3 shared papers, 2022–2023 · strength 0.48
  18. Ifeanyichukwu Chinedu Ogobuiro · 3 shared papers, 2023–2024 · strength 0.45
  19. Hong Joo Kim · 3 shared papers, 2022–2024 · strength 0.44
  20. Chet W. Hammill · 3 shared papers, 2022–2024 · strength 0.44
  21. Alexander A. Parikh · 3 shared papers, 2014–2024 · strength 0.34
  22. Rebecca Anne Snyder · 2 shared papers, 2023–2024 · strength 0.31
  23. Giuseppe Malleo · 2 shared papers, 2023–2026 · strength 0.31
  24. Ryan K. Schmocker · 2 shared papers, 2023–2026 · strength 0.31
  25. Jin Peng He · 2 shared papers, 2023–2026 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.